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This paper reports on the transformation that has occurred in the care of people living with HIV/AIDS in a Toronto Hospice.
Casey House opened in the pre-HAART era to care exclusively for people with HIV/AIDS, an incurable disease. At the time,
all patients were admitted for palliative care and all deaths were due to AIDS-deﬁning conditions. AIDS-deﬁning malignancies
accounted for 22 percent of deaths, mainly, Kaposi sarcoma and lymphoma. In the post-HAART era, AIDS-deﬁning malignancies
droppeddramaticallyandnon-AIDS-deﬁningmalignanciesbecameasigniﬁcantcauseofdeath,includinglivercancer,lungcancer
and gastric cancers. In the post-HAART era, people living with HIV/AIDS served at Casey House have changed considerably, with
increasingnumbersofpatientsfacinghomelessnessandmentalhealthissues,includingsubstanceuse.CaseyHouseoﬀersapicture
of the evolving epidemic and provides insight into changes and improvements made in the care of these patients.
1.Introduction
Remarkable changes have taken place since AIDS was ﬁrst
described in 1981. The face and complexity of both living
and dying with HIV have evolved signiﬁcantly over the
last three decades. Today, incidence is increasing in new
subpopulations, new treatments are becoming available and
individualsarelivinglongerontreatment.Therearealsonew
and unanticipated complications of this virus which result
in changing causes of death. In order to eﬀectively research,
plan,andprovidethebestcarepossibleforpeoplelivingwith
HIV/AIDS, it is essential that we understand both trends and
the current state of the epidemic today, including diﬀering
causes of mortality.
In a classic paper examining deaths of individuals who
were diagnosed with AIDS prior to 1986, the one-year
mortality rate was 51.2% and the 5-year rate was 84.8%. The
principal causes of death were P. carinii pneumonia (now
referred to as P. jirovecii pneumonia) and Kaposi sarcoma
in 82% of the cases [1]. By the mid-1990s antiretroviral
combination therapy became available. These drugs sup-
pressed HIV replication and, as a result, deaths due to HIV
infection were greatly reduced. The number of deaths in
HIV-infected persons in the United States dropped from
approximately 50,000 in 1995 to 18,000 in 2008 [2]. AIDS
deaths captured by the Public Health Agency of Canada,
which counts only voluntary reporting of death in previously
reported HIV/AIDS cases, signiﬁcantly underestimates the
number of AIDS deaths in Canada but shows a similar
declinewith1501deathsin1995and53in2008[3].Eﬀective
medications also led to the near disappearance of many2 AIDS Research and Treatment
familiar manifestations of HIV. In 1994, over 95% of the
deaths in HIV-infected persons in San Francisco were HIV
related [4]. Tracking changes in death as a result of antiretro-
viral therapies, the San Francisco study [4] found, between
1994 and 1998, deaths from wasting in HIV infected persons
declined from 252 to 44; deaths from cytomegalovirus
infection from 274 to 34; from Kaposi sarcoma from 246
to 32; and from P. carinii from 187 to 29 [4]. Declines in
these conditions, and other HIV-related conditions, have
continued. A recent study of 1597 deaths that occurred in 13
cohortsbetween1996and2006foundthatoverhalfofdeaths
in people with HIV/AIDS were not attributed to diagnoses
that have been traditionally related to HIV infection. Of
these, 23% were non-AIDS-deﬁning malignancies; 16% were
non-AIDS-deﬁning infections; 15% were related to drugs
and/or violence; 14% to liver disease [5].
The changes in prognosis and associated diagnoses
have resulted in a new burden of care on organizations
that serve HIV-infected persons. One type of healthcare
organization dramatically aﬀectedis the hospice that initially
served those dying with HIV. In the early years of the
epidemic, individuals arrived at these institutions with a
devastated immune system that resulted in multiple HIV-
related opportunistic infections and death within months.
With the advent of combination antiretroviral therapy and
an increased understanding of the clinical and medical
management of HIV-related conditions, HIV/AIDS patients
are now frequently discharged to return home to their
community. However, this population requires a range of
healthcare services to manage the extensive medication
regimes and complex medical and psychiatric comorbidities,
many of which are non-AIDS deﬁning [6–9]. With the
decline in the number of deaths in HIV-infected persons,
many AIDS hospices have closed, evolved, or expanded to
provide rehabilitation care. Thus, the changes in hospice care
over the last 30 years provide a bellwether, giving an insight
into the transformation that has occurred in HIV care.
As a means of tracing this historical change, we per-
formed a retrospective study to compare the causes of death
of those who died in a Toronto hospice, known as Casey
House, between 1988 and 2006–2008. These two time-
periods were chosen to represent the ﬁrst year of operation
of the hospice, before the development of antiretroviral
therapies, and a recent portrayal of patients in a time where
highly active antiretroviral therapies (HAART) are widely
available in developed countries. A longer time-frame in
the post-HAART period was necessary to capture similar
numbers of deaths. In another report we have described the
demographics and medical, and psychiatric comorbidity of
the entire population of patients admitted to the facility in
2008 [10]. We include some of that data here to provide
broader context of the morbidity as well as mortality
currently experienced by the patients needing care.
2. Methods
2.1. Setting. Casey House was originally established in 1988
as Canada’s ﬁrst hospice for individuals with HIV infection.
Today, Casey House is a 13-bed hospital which provides
both in-patient and home care services to people living with
HIV/AIDS. There are approximately 100 in-patient admis-
sions a year. Individuals with HIV may be admitted for sub-
acute rehabilitative care, medical and psychiatric symptom
control (including pain management), post-hospitalization
support, end-of-life palliative care, or respite care. Care is
provided by an inter-professional team including primary
and consultant specialist physicians, nurses, social workers,
and rehabilitation therapists.
2.2. Data Collection and Analysis. Ar e t r o s p e c t i v er e v i e wo f
patient charts and death certiﬁcates was undertaken at Casey
House, Toronto, Canada. The ﬁrst set of the analyses focused
onpatientswhohaddiedatCaseyHouse.Wedeﬁnedtheﬁrst
10 months of Casey House operation as the “pre-HAART”
period, thus including records of all patients who had died
between the ﬁrst day Casey House opened its doors, March
1, 1988, and December 31, 1988. In this era, Casey House
operated solely as a hospice and patients were admitted
only for end-of-life care. We compared characteristics of
these pre-HAART patients who died to all Casey House
patients who died during a 36-month time period from
January 1, 2006 to December 31, 2008. The years 2006–
2008 were chosen to represent the current epidemic in an
environment where highly-active antiretroviral therapies are
widelyavailable.Wedescribe diﬀerencesincausesofdeathin
the two time-periods. Uneven time-periods were necessary
to obtain comparable numbers of deaths in each time.
In addition to focusing on patients who died during their
tenure at Casey House, we describe the characteristics of
all patients admitted to Casey House during the entire year
of 2008 (January 1–December 31) to demonstrate how the
facility had evolved as the HIV epidemic, and consequently
survival, changed [10].
Clinical and sociodemographic characteristics were col-
lected from patient charts and death certiﬁcates. Due to
developments in medical knowledge and changes in the
scope of practice, not all variables were available or collected
for all deaths. Causes of death and types of cancer death were
identiﬁedandclassiﬁedusingtheInternationalClassiﬁcation
of Diseases, the 10th edition. Causes of death were identiﬁed
as AIDS-deﬁning conditions according to the Centers for
Disease Control and Prevention (CDC) [11]. Malignancies
were identiﬁed as AIDS-deﬁning malignancies (including all
malignancies listed by the CDC as an AIDS-deﬁning con-
dition: Kaposi sarcoma, Burkitt lymphoma (or equivalent
term), immunoblastic lymphoma, lymphoma (primary of
brain), and invasive cervical cancer) or non-AIDS-deﬁning
malignancies. Simple descriptive and chi-square statistics
were used to analyze the data.
This research project was approved by the Research
Ethics Board at St. Michael’s Hospital, Toronto, Canada.
3. Results
3.1. Patient Characteristics
Pre-HAART Era. Fifty-nine patients died at Casey House in
the 10 months between March 1 and December 31, 1988. AllAIDS Research and Treatment 3
Table 1: Demographics of patients who died in the pre-HAART and post-HAART periods.
Pre-HAART (1988) (n = 59) Post-HAART (2006–2008)
(n = 48) Statistical diﬀerence
Average age at death (n = 59;
n = 48) 39.0 (SD = 9.3; range 23–65) 48.1 (SD = 8.6; range 30–69) t(105) = 5.2, P<. 001
Gender (n = 59; n = 48): x2(1) = 6.4,
Male 59 (100%) 43 (89.6%) P = .001
Female 0 5 (10.4%)
MSM (n = 59; n = 42) 58 (98.3%) 34 (80.9%) x2(1) = 9.1, P<. 01
Average number of years since
HIV/AIDS diagnosis until death
(n = 59; n = 48)
1.5 (SD = .9; range 0–4) 13.5 (SD = 6.5; range 1–25) t(47) = 12.6, P<. 001
A v e r a g en u m b e ro fd a y si n
hospital prior to death (n = 59;
n = 48)
31.6 (SD = 29.8; range 1–159) 44.8 (SD = 57.9; range 0–228) t(67) = 1.4, P = .16
Has mental illness (n = 43;
n = 46) 16 (37.2%) 31 (67.4%) x2(1) = 9.4, P = .002
Homeless (n = 38; n = 47) 2 (5.3%) 7 (14.9%) x2(1) = 2.1, P = .15
Current smoker (n = 56; n = 46) 28 (50.0%) 25 (54.3%) x2(1) = .19, P = .66
Recreational drug use (n = 56;
n = 47) 12 (21.4%) 30 (63.8%) x2(1) = 19.0, P<. 001
Current IV drug use (n = 55;
n = 47) 4 (7.3%) 11 (23.4%) x2(1) = 5.7, P = .017
patients were male and all but one individual (98.3%) self-
identiﬁed as men having sex with men (MSM). Individuals
lived an average of 1.5 years (SD = 0.9) with an HIV/AIDS
diagnosis before dying. The mean age at death was 39.0 years
(SD = 9.3).
Post-HAART Era. Forty-eight patients died at Casey House
in the 36 months between January 1, 2006 and December
31, 2008. Forty-three (89.6%) patients who died were male.
Thirty-four (80.9%) persons identiﬁed MSM. The average
age at death was 48.1 years (SD = 8.6) after living an average
of 13.5 years (SD = 6.5) since HIV/AIDS diagnosis.
Characteristics of patients who died in the pre- and
post-HAART period are summarized in Table 1. In the pre-
HAART era 37.2% of patients had mental health issues, this
almost doubled in the post-HAART era to 67.4%. In 1988,
only 5.3% were homeless, however the number of home-
less and socioeconomically marginalized patients increased
signiﬁcantly in the post-HAART era. In terms of substance
use, the number of smokers remained relatively constant at
approximately 50%. In the pre-HAART era, 21.4% endorsed
recreational drug use and 7.3% reported injecting drugs.The
self-reported incidence of both behaviours nearly tripled in
the post-HAART era to 63.8% and 23.4%, respectively.
3.2. Cause of Death
Pre-HAART Era. The primary cause of death was identiﬁed
as an AIDS-deﬁning condition in all 59 deaths in 1988.
Twenty-two percent (n = 13) were due to AIDS-deﬁning
malignancies. Forty-two percent (n = 25) of deaths were due
to AIDS-deﬁning opportunistic infections, most commonly
disseminated Mycobacterium avium complex disease (MAC)
(n = 5), toxoplasmosis (n = 5), and Pneumocystis pneumo-
nia(PCP)(n = 3).Thirty-sixpercent(n = 21)ofdeathswere
identiﬁed as other AIDS-deﬁning conditions. In 19 of these
cases the cause of death was listed only as “AIDS.”
Post-HAART Era. Forty-eight percent of deaths in the post-
HAART era were attributed to AIDS-deﬁning conditions.
Thirty-one percent (n = 15) of individuals died of AIDS-
deﬁning opportunistic infections; 6% (n = 3) from AIDS-
deﬁning malignancies; 10% (n = 5) from other AIDS-
deﬁning conditions. The remaining 25 deaths (52%) were
attributed to: non-AIDS-deﬁning malignancies (n = 13;
27%); liver disease (n = 3; 6%); other causes (n = 9; 19%)
including multi-organ failure (n = 3) and respiratory failure
(n = 2). Fourteen patients had hepatitis B or C listed as a
contributing cause of death.
Figure 1 presents a summary and comparison of the
primary causes of death in the two time periods.
3.3. Malignancies. Malignancies accounted for 22% (n = 13)
of deaths in the pre-HAART era. All of these were AIDS-
deﬁning malignancies: 11 were attributed to Kaposi sarcoma
and 2 to lymphoma. An additional 4 deaths had Kaposi
sarcoma listed as a contributing factor. In the post-HAART
era, malignancies accounted for the primary cause of death
in 33% (n = 16) of deaths: 6% (n = 3) were due to
AIDS-deﬁning malignancies and 27% (n = 13) were due to
non-AIDS-deﬁning malignancies. Kaposi sarcoma was not
listed as the primary cause of death for any patients in the
post-HAART period but was a contributing factor in one
death. Figure 2 illustrates the frequency of diﬀerent types of4 AIDS Research and Treatment
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Figure 1: Primary cause of death in individuals who died at Casey
House in 1988 (pre-HAART) in comparison to 2006–2008 (post-
HAART).
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Figure 2: Types of malignancy in individuals who died at Casey
House in 1988 (pre-HAART) compared to 2006–2008 (post-
HAART).
malignancies present in individuals at the time of death for
the two time-points. This ﬁgure includes three individuals
in the post-HAART period that had a malignancy listed as a
contributing cause of death but not as the primary cause of
death.
In the post-HAART era, many of the non-AIDS-deﬁning
malignancies occurred in patients who were on HAART
therapy, with reasonably well-controlled disease. Admission
CD4 count was available on ten patients who died from non-
AIDS-deﬁningmalignancies,ofwhom70%hadaCD4count
greater than 200cells/mm3. CD4 counts ranged from 25–
800 cells/mm3. Of the eight patients who had admitting viral
loads, six were undetectable, and the other two had 150 and
400,000 copies/mL.
3.4. HIV/AIDS Patients Admitted in 2008. Between January
1 and December 31, 2008, 87 individuals were admitted to
Casey House. Of the 87 individuals who were admitted, 17
(n = 19.5%) died during their stay at Casey House: seventy-
percent of whom had a CD4 count below 200cells/mm3.
Of the individuals who died with decreased immune system
function, 25% were homeless and 25% lived in supportive
housing. All individuals who died with a CD4 count above
200cells/mm3 reported renting their own housing (exclud-
ing supportive housing). Table 2 includes descriptive data
for all patients admitted in 2008 and compares individuals
who died during their stay to those who were discharged.
There were no statistically signiﬁcant diﬀerences (at the P<
.05 level) between patients who died and those who were
discharged, although there were slightly more individuals
with a CD4 count below the median in those who died
(P = .07). Eighty percent of patients admitted were male.
The average age at admission was 48.9 years (SD = 10.5)
and the median CD4 count was 150 cells/mm3. The average
number of medical comorbidities experienced by patients at
the time of admission was 5.9 (SD = 2.3). The most common
being: AIDS-deﬁning opportunistic infections (n = 27;
65.9%); respiratory conditions, such as chronic obstructive
pulmonary disease, (n = 16; 39.0%), and non-AIDS-
deﬁning malignancies (n = 10; 24.4%).
4. Discussion
Looking at the evolution in rate and cause of death in a
hospice, over a twenty-year period, gives important insight
into the development of the HIV epidemic. In 1988, HIV
infected persons admitted to this facility were suﬀering from
a ravaged immune system that resulted in deaths caused by a
spectrum of diagnoses deﬁned as AIDS-related conditions.
All admissions were for palliative care. At the time, AIDS
was felt to be a hopeless diagnosis. Casey House embraced
the caring and compassionate hospice care model—often
demedicalizing the treatment of the patients, and as a result
speciﬁc investigations were not made into the particular
cause of death and many certiﬁcates simply state this patient
died of “AIDS.” In contrast, by 2008 less than 20% of patients
admitted to Casey House died during their stay. And thus,
80% were discharged, often following an in-patient stay
which included investigations and treatment for HIV as well
as management of medical comorbidities and mental health
issues. This highlights a signiﬁcant change in the type of care
needed by patients and also the lived experience of HIV-
positive individuals.
Over the 20-year period examined in this study, there
were signiﬁcant changes in both the primary cause of death
and the characteristics of those who died. In 1988, all deathsAIDS Research and Treatment 5
Table 2: Patient characteristics for all admissions in 2008.
All patients(n = 87) Patients who died
(n = 17)
Patients who survived
(n = 70) Statistical diﬀerence
Average age (n = 17; n = 70) 48.9 (SD = 10.5) 49.4 (SD = 10.1) 48.8 (SD = 10.7) t(85) = .22, P = .83
Gender (n = 17; n = 70)
Male 70 (80.5%) 14 (82.3%) 56 (80.0%)
Female 17 (19.5%) 3 (17.6%) 14 (20.0%) x2(1) = .05, P = .83
Median CD4 at admission
(n = 16; n = 67) 150.0 68.8% below median 43.3% below median x2(1) = 3.4, P = .07
CD4 admission categories
(n = 16; n = 67)
<200 48 (57.8%) 12 (75.0%) 36 (53.7%) x2(2) = 2.9, P = .24
200–500 24 (28.9%) 2 (12.5%) 22 (32.8%)
>500 11 (13.2%) 2 (12.5%) 9 (13.4%)
Average number of
comorbidities (n = 17; n = 70) 5.9 (SD = 2.3) 5.6 (SD = 2.2) 5.9 (SD = 2.3) t(85) = .53, P = .60
AIDS-deﬁning malignancy
(n = 17; n = 70) 5 (5.7%) 2 (11.8%) 3 (4.3%) x2(1) = 1.4, P = .24
Non-AIDS deﬁning malignancy
(n = 17; n = 70) 14 (16.1%) 5 (29.4%) 9 (12.9%) x2(1) = 2.8, P = .10
Psychiatric disorder (n = 17;
n = 70) 80 (92.0%) 14 (82.4%) 66 (94.3%) x2(1) = 2.6, P = .11
Cognitively impaired 41 (47.1%) 9 (52.9%) 32 (45.7%) x2(1) = .29, P = .59
Substance use disorder 36 (41.4%) 5 (29.4%) 31 (44.3%) x2(1) = 1.2, P = .26
were attributed to an AIDS-deﬁning condition, while less
than half were in the 2006–2008 time period. Malignancies
were a common cause of death in both time periods,
although the types of malignancy changed considerably.
Although the population remained largely male and mostly
among men who have sex with men, in the post-HAART
period 10% of deaths were in women. Individuals who died
in the post-HAART period also reported greater IV drug and
recreational drug use and more individuals were identiﬁed as
homeless and with a mental illness.
Surveillance data and other research reports comparing
the pre-HAART and post-HAART era show similar changes
in the demographics of the HIV epidemic and causes of
death. Although HAART has signiﬁcantly decreased mortal-
ity in HIV-positive individuals, mortality is still signiﬁcantly
higher than in the general population and there are sub-
groups that are at substantially greater risk such as injection
drug users [5]. Studies linking HIV/AIDS databases and can-
cer registries over approximately the same time period have
shown a dramatic decrease in AIDS-deﬁning malignancies
andanincreasein non-AIDS-deﬁning malignancies [12,13].
As experiencedat Casey House, the most commoncancersof
the pre-HAART era were Kaposi sarcoma and non-Hodgkin
lymphoma. Both are typically linked with low CD4 count
and coinfection with viral agents. Although such AIDS-
deﬁning malignancies remain prevalent in the HIV/AIDS
population in the post-HAART era, numbers of non-AIDS-
deﬁning malignancies have increased as much as 20% in the
US [14]. Between 2001 and 2005, the most common types
of non-AIDS-deﬁning cancers were lung cancer, anal cancer,
livercancer,andHodgkinlymphoma[13].Thisisreﬂectedat
Casey House. The Swiss cohort study notes that certain non-
AIDS-deﬁning malignancies associated with smoking such
as lip, mouth, pharynx, and lung cancers increased in the
post-HAART era. In addition, cancers of the liver associated
with Hepatitis B and/or Hepatitis C coinfection, as well as
human papilloma virus-related cancers, such as anal cancer,
were also increased. It was speculated that living longer
with disease, combined with partial immune reconstitution,
allowed long-latency cancers to progress and manifest [12].
The studies make the point that people living with
HIV/AIDS are at greater risk of cancer than the general
population, and there is a great deal of speculation as to why
this occurs. Increased cancer risk is believed to be a com-
plex interaction, with multiple factors, including impaired
immunity, co-infection with biologic agents carcinogenic to
humans (such as HPV, EBV, and hepatitis), aging, HAART,
and traditional risk factors for cancer, such as smoking
and sun exposure [15] .T h e r ei ss o m ee v i d e n c et h a tp r o -
longed immunosuppression—as assessed by CD4 nadir—is
independently linked to increased incidence of non-AIDS-
deﬁning malignancies [16]. In addition, the presence of HIV
is linked to cytokine dysregulation and this may also play a
role in increasing cancer risks [15].
Certainly there are complex factors at play in the patients
seen at Casey House, who may have as many as 6 medical
comorbidities, including coinfection with hepatitis, as well
as risk factors such as unstable housing, injection drug-use,
and smoking (approximately 50% of our patients smoke in
comparison to 21% in individuals over 12 in Canada [17]).
Individuals are now living for more than a decade with HIV
and although some have maintained CD4 counts above 200,6 AIDS Research and Treatment
with suppressed virus, many individuals are not on HAART
therapy or do not adhere to their medication regimes. It is
interesting to note that patients with reconstituted immune
systems remain at risk from cancer [18]. And, as reﬂected in
the broader epidemic, our patients include more marginal-
ized individuals who have signiﬁcant social determinants of
health risk factors such as homelessness and mental illness
and this association also places them at risk [6, 7, 19].
In response, we need to adopt eﬀective health promotion
models for HIV-infected individuals and the health care
response must be comprehensive and collaborative. Research
and service initiatives should expand their focus to address
medical preventive care including cancer screening and
treatment initiatives such as smoking cessation, as well as
social and psychosocial needs. These services and supports
must be available in various settings to address the spectrum
of needs, from case management and chronic symptom
management to acute medical interventions and end-of-life
care.
We acknowledge that this retrospective study has sev-
eral important limitations. Data extracted from charts are
susceptible to variations in reporting and diagnostic criteria
and missing data are common. The changes in reporting
practicesareampliﬁedinthisstudywheredatawerecollected
from time-points 20 years apart in a disease that has been
described for only 30 years. In 1988, many primary causes
o fd e a t hw e r ew r i t t e na s“ A I D S . ”I ti sm o s tl i k e l yt h a t
these individuals and deaths would have been evaluated
a n dr e c o r d e dd i ﬀerently today. This may underestimate
the number of individuals who died of AIDS-deﬁning
malignancies and possibly other non-AIDS-related causes of
death. In this study, death certiﬁcates and primary cause
of death were identiﬁed for all individuals but data were
incomplete for many clinical and demographic variables.
Our ability to clinically describe these patients is also limited
by the state-of-knowledge and treatments available in 1988.
Many tests routinely issued to HIV-positive individuals
today, such as CD4 counts and viral loads, either did not
exist or were not widely used in 1988. Hepatitis C was not
yet identiﬁed [20]. These ﬁndings are strengthened however
by the complete inclusion of deaths that occurred at a single
institution during the two periods of study. The description
of all patients admitted in 2008 provides further context to
the changes in the epidemic and the health care services
provided. However, because Casey House is not an acute
care hospital our study will not accurately represent the
occurrence of certain types of death such as cardiac arrest,
suicide, and trauma. It is also possible that individuals were
diﬀerentiallyreferredtoCaseyHouseinthetwotimeperiods
as clinical knowledge and stigma of the disease evolved.
5. Conclusion
In summary, our ﬁndings are consistent with other studies
in identifying changing trends in both the demographics
and causes of death in individuals dying from HIV/AIDS.
This study focuses on the patients and care provided at
an AIDS hospice that evolved with the epidemic into a
subacute hospital, giving some perspective to the ensuing
changes that have occurred in organizations and the care
supporting individuals with HIV/AIDS. As our knowledge
and treatments for HIV improve, individuals are living
longer but often with substantial psychosocial risk factors
and signiﬁcant medical and psychiatric comorbidities. Fewer
HIV-positive individuals are dying from AIDS-deﬁning
conditions and increasing numbers of individuals are dying
fromnon-AIDS-deﬁningmalignanciesandothernon-AIDS-
deﬁning conditions such as liver disease. The palliative care
model of symptom management remains important for
these patients. In order to plan and provide the care that is
n e e d e d ,i ti sc r u c i a lt h a tw ea d d r e s sb o t ht h em e d i c a la n d
psychiatric complications and the social and psychosocial
needsandrisksoflivingwithachronicdiseasethathassucha
devastatingandstigmatizinghistory.And,aslongasHIVhas
no cure, we must also continue to acknowledge and provide
care for individuals with HIV that embraces the palliative
care model.
Acknowledgments
The authors would like to acknowledge the support of David
Lightfoot, Information Specialist, for assistance in literature
searches, Sarah Stranks for data abstraction, and Maureen
Mahan for reviewing this paper. This publication was made
possible with help from the Baylor-UTHouston Center
for AIDS Research (CFAR), an NIH funded Program
(AI036211).
References
[1] R. Rothenberg, M. Woelfel, R. Stoneburner, J. Milberg, R.
Parker,andB.Truman,“Survivalwiththeacquiredimmunod-
eﬁciency syndrome. Experience with 5833 cases in New York
City,” The New England Journal of Medicine, vol. 317, no. 21,
pp. 1297–1302, 1987.
[2] Centers for Disease Control and Prevention (CDC), “HIV
surveillance—United States, 1981–2008,” Morbidity and Mor-
tality Weekly Report, vol. 60, no. 21, pp. 689–693, 2011.
[3] Public Health Agency of Canada, HIV and AIDS in Canada.
Surveillance Report to December 2009, Surveillance and Risk
Assessment Division, Centre for Communicable Diseases and
Infection Control, Public Health Agency of Canada, 2010,
http://www.phac-aspc.gc.ca/aidssida/publication/survreport/
2009/dec/8-eng.php.
[ 4 ]J .K .L o u i e ,L .C .H s u ,D .H .O s m o n d ,M .H .K a t z ,a n d
S. K. Schwarcz, “Trends in causes of death among persons
with acquired immunodeﬁciency syndrome in the era of
highly active antiretroviral therapy, San Francisco, 1994–
1998,” Journal of Infectious Diseases, vol. 186, no. 7, pp. 1023–
1027, 2002.
[5] Antiretroviral Therapy Cohort Collaboration, “Causes of
death in HIV-1-Infected patients treated with antiretroviral
therapy, 1996–2006: collaborative analysis of 13 HIV cohort
studies,” Clinical Infectious Diseases, vol. 50, no. 10, pp. 1387–
1396, 2010.
[ 6 ]F .L .A l t i c e ,A .K a m a r u l z a m a n ,V .V .S o r i a n o ,M .S c h e c h t e r ,
and G. H. Friedland, “Treatment of medical, psychiatric, and
substance-use comorbidities in people infected with HIV who
use drugs,” The Lancet, vol. 376, no. 9738, pp. 367–387, 2010.AIDS Research and Treatment 7
[7] J. Walkup, M. B. Blank, J. S. Gonzalez et al., “The impact of
mental health and substance abuse factors on HIV prevention
and treatment,” Journal of Acquired Immune Deﬁciency Syn-
dromes, vol. 47, supplement 1, pp. S15–S19, 2008.
[8] B.Hasse,B.Ledergerber,H.Furreretal.,“Morbidityandaging
in HIV-infected persons: the swiss HIV cohort study,” Clinical
Infectious Diseases, vol. 53, no. 11, pp. 1130–1139, 2011.
[9] G.Guaraldi,G.Orlando,S.Zonaetal.,“Prematureage-related
comorbidities among HIV-infected persons compared with
the general population,” Clinical Infectious Diseases, vol. 53,
no. 11, pp. 1120–1126, 2011.
[10] M.H a lma n,S.Stra nks,N.Sc hae f e r -M c Da niel,a ndA.St e w a rt,
“Medical and psychiatric comorbidities: the complexity of
care in a sample of patients with late-stage HIV disease,” in
Proceedings of the 18th International AIDS Conference, July
2010, Abstract no. CDB0018.
[11] Centers for Disease Control and Prevention (CDC), “Revised
surveillance case deﬁnitions for HIV infection among adults,
adolescents, and children aged <18 months and for HIV
infection and AIDS among children aged 18 months to <13
years—United States, 2008,” Morbidity and Mortality Weekly
Report, vol. 57, no. 10, pp. 1–12, 2008.
[12] G. M. Cliﬀord, J. Polesel, M. Rickenbach et al., “Cancer risk
in the Swiss HIV cohort study: associations with immunod-
eﬁciency, smoking, and highly active antiretroviral therapy,”
Journal of the National Cancer Institute, vol. 97, no. 6, pp. 425–
432, 2005.
[13] M. S. Shiels, R. M. Pfeiﬀe r ,M .H .G a i le ta l . ,“ C a n c e rb u r d e n
in the HIV-infected population in the United States,” Journal
of the National Cancer Institute, vol. 103, no. 9, pp. 753–762,
2011.
[14] E. P. Simard, R. M. Pfeiﬀer, and E. A. Engels, “Spectrum of
cancer risk late after AIDS onset in the United States,” Archives
of Internal Medicine, vol. 170, no. 15, pp. 1337–1345, 2010.
[15] M. L. Nguyen, K. J. Farrell, and C. J. Gunthel, “Non-AIDS-
deﬁning malignancies in patients with HIV in the HAART
era,” Current Infectious Disease Reports, vol. 12, no. 1, pp. 46–
55, 2010.
[16] N. Dauby, S. de Wit, M. Delforge, V. C. Necsoi, and N. Clu-
meck, “Characteristics of non-AIDS-deﬁning malignancies in
the HAART era: a clinico-epidemiological study,” Journal of
the International AIDS Society, vol. 14, no. 1, article 16, 2011.
[17] Statistics Canada, CANSIM, table 105-0501 and Catalogue
no. 82-221-X, 2011, http://www40.statcan.gc.ca/l01/cst01/
health74b-eng.htm.
[18] M. J. Silverberg, C. Chao, W. A. Leyden et al., “HIV infection,
immunodeﬁciency, viral replication, and the risk of cancer,”
Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 12,
pp. 1–9, 2011.
[19] R. S. Hogg, S. A. Strathdee, K. J. Craib, M. V. O’Shaughnessy,
J. S. G. Montaner, and M. T. Schechter, “Lower socioeconomic
status and shorter survival following HIV infection,” The
Lancet, vol. 344, no. 8930, pp. 1120–1124, 1994.
[20] H. Alter, “Discovery of non-A, non-B hepatitis and identiﬁca-
tion of its etiology,” AmericanJournalofMedicine,vol.107,no.
6, pp. 16S–20S, 1999.